Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Cell Signaling Technology (CST) has launched a highly specific PD-L1 rabbit monoclonal antibody (mAb).
Subscribe to our email newsletter
The recent reports have demonstrated PD-L1 to be up-regulated on the surface of tumor cells, implicating this protein as one of the factors that allows tumors to evade the immune system.
The company’s PD-L1 Rabbit mAb is a najor addition for researchers studying tumor immunology and potential approaches to immunotherapy for melanoma, lung, ovarian, renal, prostate, and other cancers.
Clinical researchers are assessing antibodies to PD-L1 as potential cancer biotherapeutics (Brahmer, J.R., et al. (2012) New Engl J Med 366,2455-65).
The company said that PD-L1, whose binding leads to inhibition of T cell activity, interacts with PD-1, a surface receptor on activated T cells.
Immunohistochemistry (IHC) is a major important application for studying the role of PD-L1 in human and/or mouse xenograft samples, and the company’s PD-L1 (E1L3N) XP Rabbit mAb #13684 has been validated for recognition of human PD-L1 in IHC as well as for immunofluorescence, flow cytometry, western blot, and immunoprecipitation.
The high specificity and sensitivity of the antibody are supported by western blot detection of a single band at the appropriate molecular weight and by the IHC detection of endogenous levels of PD-L1 in tumor cells.